脂蛋白 (a) 作为急性冠状动脉综合征的预测生物标志物和治疗标
Yannis Dimitroglou1, Constantina Aggeli1, Panagiotis Theofilis1
11st Cardiology Clinic, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Current pharmaceutical design
|June 2, 2023
概括
脂蛋白 (a) [Lp(a) ]是一种与心血管风险增加相关的基因确定生物标志物. 针对Lp (a) 的新疗法显示有望降低高风险患者的心血管死亡率.
科学领域:
- 心脏病学和动脉样硬化研究
背景情况:
- 冠状动脉疾病 (CAD) 仍然是导致死亡的主要原因,尽管预防方面取得了进展.
- 脂蛋白 (a) [Lp(a) ]是一种基因决定的生物标志物,具有益动脉动脉,益血栓和益炎性质.
- 升高的Lp(a) 水平独立地与急性冠状动脉综合征 (ACS) 风险增加有关.
结论:
- 新型疗法,包括反感性寡核酸和小干扰RNA,有效降低Lp (a) 水平.
- 目前正在进行的第三期试验将确定Lp (a) 向治疗是否可以降低心血管死亡率.
- Lp (a) 正在成为高风险心血管患者的特定治疗点.
相关概念视频
Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
Acute Coronary Syndrome III: Diagnostic Studies
12
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
12
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
24
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
24
Atherosclerosis III: Management
16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
717
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
717
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
127
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
127


